Loading...
Loading...
RXi Pharmaceuticals Corporation
RXII today announced that dosing with their first drug in its
first Phase 1 study, was completed last week. RXI-109 is being developed
to prevent or reduce dermal scarring following surgery or trauma, as
well as for the management of hypertrophic scars and keloids. Over the
past 3 months, 15 subjects who are scheduled to undergo abdominoplasty
in the coming months, were enrolled in a double-blind dose, escalation
study during which single intradermal injections were administered in a
dose dependent manner to 5 cohorts of 3 subjects each. Subjects received
an injection of RXI-109 in 2 separate areas on
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in